Onset and duration of action of single doses of formoterol inhaled via Turbuhaler®

Respiratory Medicine

Volumn 92, Issue 8, 1998, Pages 1017-1021

  Ringdal, N ^a   Derom, E ^b   Wahlin Boll E ^c   Pauwels, R ^b  

^a Medical Department   (Norway)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; FORMOTEROL;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREMOR;

EID: 0031667891     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90348-1     Document Type: Article

References (19)

1. Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991; 42: 115-137.
2. Wegener T, Hedenström H, Melander B. Rapid onset of action of inhaled formoterol in asthmatic patients. Chest 1992; 102: 535-538.
3. Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long-acting sympathomimetic. Thorax 1992; 47: 30-33.
4. Kesten S, Chapman KR, Broder I et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis 1991; 144: 622-625.
5. 2-agonist formoterol. Am Rev Respir Dis 1991; 143: 988-1001.
6. Wallin A, Melander B, Rosenhall L, Sandström T, Wåhlander L. Formoterol, a new long-acting β2-agonist for inhalation twice daily, compared with salbutamol in treatment of asthma. Thorax 1990; 45: 259-261.
7. Wallin A, Sandström T, Rosenhall L, Melander B. Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. Thorax 1993; 48: 611-614. Correction Thorax 1993; 48: 1188.
8. Maesen FP, Costongs R, Smeets SJ, Zweers PGM, Goedhart DM. Formoterol as dry powder inhalation. A dose finding study in comparison with formoterol metered dose inhaler and placebo. Chest 1992; 101; 1376-1381.
9. van den Berg BTJ, Smeets JJ, van Boxtel CJ, Maesen FPV. Evaluation of different doses of formoterol from a newly developed powder inhalation device in asthmatic patients. Fundam Clin Pharmacol 1995; 9: 593-603.
10. Borgström L, Derom E, Ståhl E, Wåhlin-Boll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153: 1636-1640.
11. Agertoft L, Pedersen S. Importance of the inhalation device on the effect of budesonide. Arch Dis Child 1993; 69: 130-133.
12. Fieller EC. Some problems in biological assay. J Statist Soc 1954; 816: 175-185.
13. 2 adrenoceptor agonist. Int J Clin Pharmacol Therapy Toxicol 1993; 31: 23-26.
14. van Noord JA, Smeets JJ, Raaijmakers JAM, Bommer AM, Maesen FPV. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration in action. Eur Respir J 1996; 9: 1684-1688.
15. Maesen FPV, Smeets JJ, Gubbelmans HLL, Zweers PGMA. Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours. Chest 1990; 97: 590-594.
16. Schreurs AJM, Sinninghe Damsté HEJ, de Graaff CS, Greefhorst APM. A dose-response study with formoterol Turbuhaler® as maintenance therapy in asthmatic patients. Eur Respir J 1996 9: 1678-1683.
17. Brusasco V, Ringdal N, Ekström T, Sobradillo. Effect of formoterol 6 μg b.i.d. via Turbuhaler® for 3 months in asthma: comparison with terbutaline and placebo. Eur Respir J 1995; 8 (Suppl. 19): 158s (abstract).
18. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484-2489.
19. Lipworth BJ, Mcdevitt DG, Svedmyr N. Beta-adrenoreceptor responses to inhaled salbutamol in normal subjects. Eur J Pharmacol 1989; 36: 239-245.